

PATENT

Attorney Dkt. No. 7372/72249

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): ASAKO, et al.) Appln No.: 10/004,115 Filed: December 6, 2001 Title: PROCESS FOR PRODUCING OPTICALLY ACTIVE 4-HALO-3-**HYDROXYBUTANOATE** Date Group Art Unit: 1651 Examiner: Not Yet Known

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327,

Arlington, VA 22202, on this date.

July 30, 02

Registration No.

Attorney for Applicant(s)

U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

Sir:

Transmitted herewith is an amendment/reply in the above-identified application.

- Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure
- Statement Concerning Sequence Listing
- ☑ Preliminary Amendment
- Written Sequence Listing
- Sequence Listing in computer readable form as required by 37 C.F.R. §1.821(e)
- ☑ No additional fee is required.

* At least 20

Fee Calculation For Claims As Amended

	As Amended		Previously Paid For		Present Extra		Rate	Δ	dditional Fee
Independent Claims	0	-	3	**=	0	x \$	84.00	= \$	0.00
Total Claims	0	-	12	* =	0	x \$	18.00	= \$	0.00
Fee for Multiply Dependent Claims				\$ 280.00					
* * At least 3				Total Additional Fee				\$	0.00

	A check in the amount of \$ is attached.
므	Charge \$ to Deposit Account No. 06-1135.
	The Commissioner is hereby authorized to charge any additional fees which may be required in this application under 37 C.F.R. §§1.16-1.17 during its entire pendency, or credit any overpayment, to Deposit Account No. 06-1135. Should no proper payment be enclosed herewith, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 06-1135. A duplicate copy of this sheet is enclosed.

July 30, 2002 Date

Kathleen A. Ranney
Registration No. 37,702

FITCH, EVEN, TABIN & FLANNERY Suite 1600 120 South LaSalle Street Chicago, Illinois 60603-3406 Telephone: (312) 577-7000

FILING RECEIPT DATE 10/004,115 12/06/2001

COMMISSIONER FOR PATENT UNITED STATES PATENT AND TRACEMARK OFFICE WASHINGTON, D. J. 20231

WWW LSCTO.CCV

FIRST NAMED APPLICANT Hiroyuki Asako

ATTORNEY DOCKE NUMBER

FITCH EVEN TABIN AND FLANNERY 120 SOUTH LA SALLE STREET **SUITE 1600** CHICAGO, IL 60603-3406

CONFIRMATION NO. 3895 FORMALITIES LETTER

Date Mailed: 05/29/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19. 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202
PART 1 - ATTORNEY/APPLICANT COPY